BOSTON -- (BUSINESS WIRE) --
Analysis Group, a leading provider of economic, financial, and strategy consulting, and health care outcomes research and services, welcomes new academic affiliate Professor Gordon Liu to the firm.
Dr. Liu is a professor of economics and the director of China Center for Health Economics Research at Peking University's Guanghua School of Management. He is a leading expert on health and development economics, health policy reform, and pharmaceutical economics in China, and a key figure in Chinese health care reform efforts.
"We are delighted to welcome Dr. Liu to our distinguished group of health care experts," said Analysis Group President and CEO Martha S. Samuelson. "He brings a deep knowledge of international health care policy and economics to our practice - a perspective that is critical as we respond to clients' growing needs for high-quality analyses in China."
Dr. Liu has undertaken several research projects funded by the State Council Health Reform Office, the National Science Foundation, UNICEF, the World Bank, and the China Medical Board. He serves on the State Council Health Reform Advisory Commission and is president of the Chinese Society for Pharmacoeconomics and Outcomes Research. He previously served as president of the Chinese Economists Society and was the founding chair of the Asian Consortium for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). "My colleagues and I look forward to collaborating with Dr. Liu," said Managing Principal Eric Q. Wu. "His multifaceted understanding of China's health care reform efforts and the country's pharmaceuticals market will complement and strengthen Analysis Group's research capabilities and further our goal of providing high-quality consulting services globally."
"The quality and rigor that Analysis Group teams apply to health outcomes research hold great appeal for those of us in the academic and scientific communities in China," said Dr. Liu. "By affiliating with Analysis Group, we can play a central role in business planning and policy discussions as stakeholders across China and the global health care industry seek balance between the efficacy of treatments and the pressures of cost containment."
Dr. Liu is a coeditor of Value in Health, the journal of ISPOR, and the editor in chief of the China Journal of Pharmaceutical Economics. Additionally, he is on the editorial boards of the Global Handbook of Health Economics, Chinese Journal of Health Economics, and the European Health Economic Review. Prior to joining Peking University, Dr. Liu was a tenured associate professor at the University of North Carolina at Chapel Hill and an assistant professor at the University of Southern California.
He earned a Ph.D. in economics from The Graduate Center at City University of New York; an M.S. in statistics from Southwestern University of Finance and Economics; and a B.S. in mathematics from Southwest University for Nationalities.
With more than 550 professionals with advanced degrees and expertise in health outcomes research, epidemiology, strategy, biostatistics, economics, and other quantitative disciplines, Analysis Group (www.analysisgroup.com) has established a leadership role in the science, economics, and business strategy of the global health care industry.
CONTACT:
Analysis Group
Eileen Harrington, 617-425-8193
eharrington@analysisgroup.com